Introduction
Recent decades have seen very large declines in cardiovascular disease (CVD), and coronary heart disease (CHD) mortality specifically, across the European Union (EU), with rates of CVD mortality falling by .30% in both sexes and CHD mortality falling by a third in men and over a quarter in women between 1985-89 and 2000 -04. 1 These trends have been attributed to improved treatment and care, which has helped to reduce case-fatality ratios, as well as improved primary prevention and risk factor management which has reduced incidence rates of disease. 2 Cardiovascular disease remains, however, the main cause of death in most European countries, with CHD and stroke accounting for the majority of these deaths. 3 Furthermore, many risk factors for CHD, particularly obesity 4 and diabetes, 5 have been increasing substantially over the same period, 6 while rates of hypertension have plateaued after substantial declines. Trends in the prevalence of these risk factors vary widely between countries and age groups, and it is not yet clear what impact these changes will have on mortality rates in the context of improved treatment and care for CHD. Smoking rates are still quite high on a world scale in some EU countries, despite a general trend to reductions in smoking prevalence, and it is probable that this contributes to inequalities in the region. 3 It is hypothesized that recent upwards trends in obesity and diabetes may be beginning to cancel out the beneficial effect of reduced smoking rates and improved care and treatment on CHD mortality, and that this effect may be demonstrated by examining CHD mortality trends in younger age groups. Although mortality rates in younger age groups make a relatively small contribution to total CHD mortality, developments in younger age groups are important indicators for public health, which may represent a cohort effect that-if maintained-would result in significant future impacts on the burden of CHD. 7 Evidence of CHD mortality rates beginning to plateau in younger age groups has been demonstrated to varying extents and at differing time points in England and Wales, 7, 8 Scotland, 9 USA, 10 and Australia. 11 The aim of this study is to investigate whether plateauing of mortality rates in younger age groups is demonstrated in an examination of age-and sex-specific trends in CHD mortality rates between 1980 and 2009 in the member states of the EU.
Methods
Data on cause-specific numbers of deaths and population numbers, by sex and in 5-year age groups (up to 85 and over) for each country of the EU, were extracted from the WHO global mortality database. Age-and sex-specific mortality rates were calculated and aggregated rates were standardized to the European Standard Population 12 using the direct method. Coronary heart disease as a cause of death was defined according to the following International Classification of Disease codes: ICD-10 (International Classification of Diseases, tenth revision) codes I20-I25; ICD-9 and ICD-8 codes 4100-4149. Data were extracted and analysed for the years 1980 (or the establishment of the present-day country if later) to 2009 where available. In some countries, death registration or population data were missing for some years. Cyprus was excluded from analyses due to a high level of unreliable and missing data. Data for Germany for years prior to 1990 were obtained by combining death registration and population data for the former Democratic Republic of Germany and the former Federal Republic of Germany and calculating overall rates. England, Wales, Scotland, and Northern Ireland were analysed together as the UK. The age groups analysed were (i) ,45 years, (ii) 45-54 years, (iii) 55 -64 years, and (iv) 65 years and over. All age groups up to 45 years were combined due to the low numbers of deaths before this age, and because subgroups that contain any year with 0 deaths must be excluded from joinpoint analyses.
Age-standardized mortality rates by country, sex, and age group were calculated. In the descriptive tables, 5-year average mortality rates are presented, to show more representative and stable rates and minimize the effect of year-to-year fluctuations in death rates, (particularly among younger age groups where rates are relatively low and therefore percentage changes over time are more affected by small absolute changes in rates). The average rate in the five most recent years of data (2005 -09) was compared with earlier 5-year periods to describe crude proportional changes in death rates over time. Data for mortality rates in all individual years were, however, used in the joinpoint analysis.
Joinpoint regression was performed to identify periods with statistically distinct log-linear trends in death rates from CHD over time within each age group, by sex and country. This analysis identifies inflexion points ('joinpoints') at which there is a significant change in the trends, using a series of permutation tests, with Bonferroni adjustment for multiple comparisons. The two-sided significance level was set at p , 0.05 for all tests. The number and location of significant joinpoints for each country by sex and age group (maximum of 3) was determined using a log-linear model, and the annual percentage change within each segment calculated. Use of a log-linear model enables the analysis of constant percentage (rather than absolute) change in prevalence over time.
The log-linear model is also more robust in rare conditions, as CHD generally is in younger subpopulations. 13 Evidence to suggest a recent plateau in a population group was defined as the situation where the final joinpoint segment (in the best fitted model) was less steeply negative compared with the preceding segment (or indeed, was flat or positive), that is, that the final segment showed less of a decrease than the segment before it. Average annual percentage changes (AAPCs) were also calculated overall (1980 -2009) and separately for each decade with respect to the underlying joinpoint model. All analyses were conducted using Stata version 11.2 (StataCorp, TX, USA) and Joinpoint Regression Program version 3.5.4 (Statistical Research and Applications Branch, National Cancer Institute, USA). Table 1 provides an overview of the available years of data and the population size, total numbers of deaths, and CHD deaths by country and sex for 2009 (or the most recent year available). Complete data for all 30 study years were available in just over half (14) of the 26 countries included. A further three countries had 29 years of data available, two had 28 years, and three had 27 years. The lowest data availability was for Slovakia, where data were only available from 1992 onwards (18 years), followed by Belgium (23 years). There were more CHD deaths among men than women in 19 of 26 countries in 2009, and a higher percentage of deaths among men were caused by CHD in 18 countries.
Results
Average annual percentage changes: overall trends in mortality Figures 1 and 2 summarize the AAPCs for CHD mortality by country, age group, and sex overall and for each decade. Almost all countries in the EU have demonstrated very large and significant decreases in death rates from CHD in the last three decades among both men and women when all ages were considered together ( Table 2) . In many countries, age-standardized mortality rates in 2005-09 were less than half what they were in 1980-84.
The median AAPC for all age groups combined between 1980 and 2009 was 22.7% for men and 22.4% for women. The largest decreases in mortality rates were in Denmark, Malta, the Netherlands, Sweden, and the UK (AAPCs ≤ 24.0% among men and ≤ 23.9% among women from 1980 and 2009) ( Table 2 ). The exceptions to these significant decreases in mortality rates among men were in Hungary, Latvia, Lithuania, and Poland (negative but non-significant AAPCs 1980-2009) and Romania (significantly positive AAPC of 1.0%). Among women, non-significant changes were found in Greece, Hungary, Lithuania, Poland, Romania, and Slovakia. No country showed significantly positive AAPCs for women of all ages combined between 1980 and 2009. In the most recent decade, the general pattern was for larger annual decreases in mortality than overall or in previous decades in nearly all countries. Among both men and women, the median AAPC between 2000 and 2009 was 24.1%.
Mortality rates from CHD before age 45 ranged between 2.1 and 14.6 per 100 000 among men, while the rate was ,2 per 100 000 among women in 23 of 26 countries. Although absolute mortality rates among young adults are low compared with older age groups, in percentage terms, CHD mortality rates (up to 45 years) deceased between 1980 and 2009 at an equal or greater rate than for all ages combined in 22 of 26 countries for men and around half of countries for women ( Table 3) . A very notable exception to this was Greece, where for both men and women, it was the only country to record a net increase in age-standardized CHD mortality rates for those aged ,45 years. In most countries, the annual decrease in mortality among those aged under 45 years in the 2000 s was as great or greater than the overall and earlier decreases. The AAPCs for the full range of years in the 65 and over age group were generally somewhat smaller than in the younger age groups, with a median AAPC of 22.3% among men and 22.2% among women between 1980 and 2009. Full details of the trends in other age groups are included in Supplementary material online, Tables S1-S4.
Joinpoint analysis: identifying inflexion points and evidence for plateaus in mortality trends
Joinpoint analyses revealed wide variation in trends of CHD mortality over the last three decades and little in the way of clear patterns within or between age groups and sexes. In each of the age and sex groups examined, there was a mixture of countries demonstrating continuous linear trends (no joinpoints identified) and models which contained one to three joinpoints over the 30 years of analysis. EU trends in age-specific coronary heart disease mortality
In all age groups and both sexes, there were a number of countries that had segments of significantly positive trend in mortality, although these were clearly the exceptions. (where the rate of CHD mortality decrease in the most recent period was less pronounced than the previous period in the model) was seen in at least one age group of men from 15 countries, and women from 12 different countries. Countries from all geographical parts of Europe were represented in this group, as were older and newer members of the EU. While there was variability between age groups, there was little to suggest a consistent pattern of plateauing among younger adults (aged under 45 or aged 45 -54 years) when compared either to the older age groups, or to all ages combined. In each of the age groups, the countries in which the most recent segment of trend showed evidence of a possible plateau were outnumbered by the countries in which the most recent trend in CHD mortality was a steeper decrease than previously. Owing to the relatively small numbers of deaths in younger age groups, resulting in less stable rates from year-to-year and reduced statistical power, there were noticeably more countries for which there were no joinpoints identified in the two younger age groups.
In the majority of subgroups for which there was evidence of a recent plateau in trends, the trend in the most recent segment still represented a statistically significant annual decrease in CHD mortality. There was only one subgroup for which the final segment was significantly positive after a previous decline; women aged under 45 in Lithuania (APC +6.1%, 2000-2009). In addition, there were three subgroups (all in Greece) for which no joinpoints were identified, but the trend over the entire 30 years of analysis was significantly positive; both sexes aged under 45 (women APC +2.6%, men APC +0.7%), and women 45-54 years (APC +1.3%).
Evidence of a recent plateau was shown for all age groups combined in two countries for both sexes (Czech Republic and Ireland) and three further countries among men only (Latvia, Malta, and Poland).
On examining the two younger age groups, there was evidence of recent plateauing of trends in six countries each for men and women in the under 45 year age group, although these were not all the same countries (Latvia, Lithuania, and the UK for both sexes; plus Italy, Poland and Slovakia among men; and Czech Republic, France, and Italy among women). In the 45 -54 year age group, Latvia and the UK again showed evidence of a possible plateau in mortality among both sexes, as did Lithuania for women and Sweden, Austria, Czech Republic, and Slovakia for men. Greek women in this age group showed a constant, significantly increasing trend over the entire period of analysis (APC +1.3%, no joinpoints identified).
Discussion
Across the EU as a whole, there is little evidence to support the hypothesis that there has been a consistent pattern of recent plateaus in CHD mortality rates, or that any recent plateaus have occurred largely or exclusively in younger age groups. Overall, the rate of decrease in CHD mortality appears to be either stable or accelerating in the majority of countries and age groups, across both sexes. Specifically in younger age groups, the proportional rates of decline in premature CHD mortality appear to be broadly similar to the rates of decline observed in older populations in the EU as a whole. In the majority of countries, the most recent reductions in AAPC in CHD mortality were as great as or greater than they have been previously.
There is, of course, substantial heterogeneity across the EU, and when individual countries are examined, it is clear that there are some countries with cause for concern, where rates of decrease in CHD mortality do appear to have slowed, including in the UK, consistent with previously published work. 7 -9 In addition there are two countries (Greece and Lithuania) in which CHD mortality rates have begun to significantly increase in recent years or decades in younger subpopulations.
Given the relative scarcity of high quality age-specific data on most CHD risk factors, it is difficult to draw conclusions about the reasons for the plateauing or increasing trends observed among younger age groups in some countries. In those countries that have experienced increases in CHD mortality rates (Greece and Lithuania), the evidence appears to suggest that overall rates of major CHD risk factors are relatively high by European standards. In Greece, where CHD mortality has increased steadily from a very low base in the 1980s, rates of diabetes and hypertension are low by European standards. Conversely, in 2009, Greece had the highest smoking rates in the EU (42% of adults overall), and smoking rates among those aged 25 -54 year old (54-57%) were more than double the rate among those aged 55 years and over (23%). 14 The most recent available data show that Greece also had one of the highest adult obesity prevalence rates in Europe; however, these data are drawn from a subnational sample and are now 10 years old. 15, 16 Among children, data from 2010 showed that .40% of Greek children aged 10 -12 years were overweight or obese, the highest rate in the EU. 17, 18 For Lithuania as well, there is a paucity of age-specific data on risk factors for CHD mortality. There is, however, evidence of an increase in smoking among young people, at least until 2002, 19 and of a trend to increasing diabetes prevalence among adults. 3 There is also evidence of high rates of risk factors for NCDs overall. 20 Conversely, some recent studies have indicated that obesity prevalence may be decreasing among Lithuanian adults, although these estimates are based on self-reported data, which may introduce a degree of bias. 21 In many cases, the AAPCs found in this study for the full range of years showed greater reductions in CHD mortality among younger age groups when compared with the 65 years and older group. This apparently smaller reduction in mortality among older adults may be a result of delayed rather than averted CHD mortality, where reductions in mortality among (for example) those aged 65 -74 are partially offset by lower rates of reduction among the very old.
The existing body of published evidence on this topic has provided very important evidence, in a number of individual countries in Europe and beyond, 7 -11,22 that despite overall very impressive reductions in CHD mortality in recent decades, it is possible that the increasing prevalence of risk factors, such as diabetes and obesity, and plateaus in the prevalence of hypertension, are attenuating these reductions for younger populations. While this is clearly true in some countries, our study has demonstrated that there is in fact substantial variation between EU countries in how these trends are playing out. It remains very plausible that observed increases in preventable risk factors for CHD will have an impact on mortality rates in all age groups including young adults in the future. This effect is, however, not yet clearly apparent across the EU, and there may still be time for public health policy and action to have an impact on these risk factors to prevent such impacts. It is crucial that future research continues to monitor trends in CHD risk factors and mortality across the EU and to examine the relationships between preventable risk factors and CHD among younger adults. Any indications of potential plateauing of CHD mortality trends among younger age groups-which were evident in this study for some countries but not yet for the EU as a wholewould be an important advance warning of potentially very high future burden of CHD as the cohort ages. An important consideration in interpreting the trends observed in this study is the limitation inherent in using mortality as the sole outcome. Given the very low rates of CHD mortality among younger age groups, it could be the case that mortality rates in this age group have been stable or decreasing despite an increase in incidence in CHD. Indeed, there is some evidence from France that younger female patients comprised an increasing proportion of hospital presentations for myocardial infarction between 1995 and 2010. 23 If this is the case across Europe, these less favourable trends in incidence among younger populations may yet translate into increased CHD mortality rates in the future. Further research is needed to determine the underlying trends in incidence and case -fatality rates among varying age groups. In addition, further exploration of trends in sudden death rates would provide important insights into the changing epidemiology of CHD in Europe. The method used to define 'recent plateau' in trends brings together joinpoint analyses across a very large number of subgroups (260) and enables assessment at the EU level of whether there is an emerging overall pattern of plateauing trends in CHD mortality rates. This synthesis is, however, necessarily a simplification which provides an overview of the patterns across 26 countries, but may not give a holistic indication of a 'recent plateau' for a small number of subgroups or countries. This is especially the case where some segments of trend are very brief in the joinpoint model that was fit to the data. As an example, women aged under 45 years in France were classified as having 'evidence of a recent plateau' as the most recent joinpoint segment has an APC of 20.6%, while the preceding segment had an APC of 213.4%. The first segment, however, only spans the years 1980-1982, and after that period there has been a consistent annual percentage reduction in mortality rates. In addition, while these segments are significantly different in trend to each other, only the most recent segment is statistically significantly different from 0. An additional potential limitation of the joinpoint analysis approach used in this study was the setting of a maximum limit of three joinpoints in the model. While a greater number of joinpoints may have created models with a closer fit to the observed data, the maximum three joinpoints were identified only in relatively few of the subgroups analysed, particularly for women and younger age groups.
The mortality and population data compiled by the WHO offer an extremely valuable resource to enable large-scale analysis and intercountry comparisons such as those in this study. While the data are generally of high quality, and in the EU, generally have very high coverage, there are limitations to using internationally aggregated vital statistics, and direct comparisons between countries require some caution. There is variability between countries in both the coverage and the quality of the vital statistics databases collected and reported to the WHO. In addition, there is variability between countries in ICD coding practices. For instance in France, it has been documented that CHD deaths are under-reported compared with other countries, and a high proportion of deaths are coded as 'other causes', meaning the true rates of CVD and CHD deaths are likely to be higher than recorded. 24 Further limitations of the data include missing years for some countries, and the necessity for historical studies to take in periods of time spanning the use of several versions of the ICD. The effect of this last limitation, is however, minimized by the use of relatively broad disease categories, for which the implications of coding changes are small. 
Conclusion
The last three decades have seen significant reductions in CHD mortality in all age groups and both sexes in most EU countries and to date, there is little evidence to suggest that these reductions are plateauing in younger age groups across the EU as a whole. However, in a small number of countries there was evidence of recent plateauing in some age groups. It remains vitally important for the whole EU to monitor and work towards reducing preventable risk factors for CHD and other chronic conditions to promote wellbeing and equity across the region.
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